Ironwood Pharmaceuticals (IRWD) Q3 2024 earnings summary

Executive summary

• LINZESS prescription demand grew 13% year-over-year in Q3 2024, marking the seventh consecutive quarter of double-digit new-to-brand growth, despite ongoing pricing headwinds from increased Medicaid mix.

• Apraglutide NDA submission for short bowel syndrome remains on track for Q1 2025, with strong phase 3 data and positive expert feedback supporting its potential as a first-choice therapy.

• Strategic pipeline decisions included not exercising the CNP-104 license option and ending new recruitment in the IW-3300 phase 2 study, focusing resources on high-value programs.

• Generated $10 million in operating cash flow and delivered $26 million in adjusted EBITDA for Q3 2024.

• Ended Q3 2024 with $88 million in cash and cash equivalents, and $400 million outstanding on the revolving credit facility.

Financial highlights

• LINZESS U.S. net sales were $226 million in Q3 2024, down 19% year-over-year; year-to-date sales declined 13% compared to the same period in 2023.

• Ironwood's Q3 2024 revenue was $91.6 million, a 19% decrease year-over-year.

• GAAP net income for Q3 was $3.6 million ($0.02 per share); Adjusted EBITDA reached $26.2 million.

• Non-GAAP net income for Q3 2024 was $3.9 million.

• Cash and cash equivalents at quarter-end were $88.2 million.

Outlook and guidance

• Full-year 2024 guidance reiterated: LINZESS U.S. net sales expected between $900–$950 million, Ironwood revenue $350–$375 million, and Adjusted EBITDA greater than $75 million.

• Pricing headwinds for LINZESS expected to persist into 2025, with more detailed guidance to be provided early next year.

• Focus remains on maximizing LINZESS profits and cash flow, and advancing apraglutide toward approval and launch.